Intermittent Oral Tube on Feeding Amount
Launched by COPKA SONPASHAN · Mar 18, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how two different methods of feeding can affect the nutritional intake of patients who have had an ischemic stroke, which is a type of stroke caused by a blockage in the blood supply to the brain. Participants will be randomly assigned to one of two groups: one group will receive nutrition through an Intermittent Oro-esophageal Tube, while the other group will use a Nasogastric Tube. Both groups will also receive standard rehabilitation treatment. The goal is to see if the method of feeding can improve the amount of food patients can take in and their overall nutritional health.
To be eligible for this trial, participants must be over 18 years old and diagnosed with ischemic stroke, along with having difficulty swallowing confirmed by a specific test. They should also be alert and stable, without a history of prior strokes. People with certain health conditions, such as severe liver or kidney problems, or those who are pregnant or nursing, will not be included in the study. If you decide to participate, you can expect to receive either of the two feeding methods and be monitored for changes in your nutritional status throughout the trial. This study aims to find better ways to support nutrition for stroke recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\>18 years.
- • Meeting the diagnostic criteria for ischemic stroke .
- • Dysphagia confirmed by Videofluoroscopic Swallowing Study.
- • Clear consciousness.
- • No history of prior stroke.
- • Stable vital signs.
- Exclusion Criteria:
- • Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc.
- • Complicated with severe liver and kidney failure, tumors, or hematological disorders.
- • Simultaneously in need to undergo other therapy that might affect the outcomes of this study.
- • Pregnant or nursing females.
About Copka Sonpashan
Copka Sonpashan is a leading clinical trial sponsor dedicated to advancing innovative therapeutic solutions through rigorous research and development. With a focus on enhancing patient care, the organization specializes in designing and executing clinical trials across various therapeutic areas, ensuring compliance with regulatory standards and ethical guidelines. By fostering collaboration with healthcare professionals and leveraging cutting-edge technologies, Copka Sonpashan aims to expedite the drug development process while maintaining a steadfast commitment to patient safety and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Nieto Li
Study Chair
Site Coordinator of United Medical Group located in Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported